And thats after they were targetting cancer, then changed to more specific blood bourne cancers. It seemed that blood bourne canxer was the first point of contact for iv fpp's so surely they need the cell specific fpp's to work if they target other irgans. TAT is definately a good question as it would seem it is pretty much unused so it wouldnt matter how many times better we are.
Ann: Fourfold Delivery Improvement in a New Lead Candidate, page-37
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |